Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks.

Adv TherJun 18, 2026 (epub)
Clinical ResearchAllergy & ImmunologyMedical GeneticsOpen access

Raffi Tachdjian, Nihal Narsipur, Paranjoy Saharia et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic literature review evaluated 12 phase 2-3 randomized clinical trials for on-demand treatments of hereditary angioedema (HAE) attacks. It found significant variability in trial designs and outcomes, with center-based trials showing longer treatment times (median, 215-630 min) compared to a home-based trial (35-51 min).

Key findings

  • Center-based trials required treatment within 5-8 hours post-attack, while home-based treatment allowed immediate intervention.
  • Median treatment times were 215-630 minutes for center-based trials versus 35-51 minutes for the home-based trial.
  • Censoring rates in placebo arms exceeded 50% in some trials, affecting data comparability.
  • Eight trials used time to onset of symptom relief as the primary endpoint, with varying definitions.

Why it matters

Understanding the heterogeneity in trial designs and outcomes is crucial for clinicians to interpret the efficacy of HAE treatments and to inform future research directions.

Source

PubMed · PMID 42313271Free full text on PubMed Central

Published in Adv Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Allergy & Immunology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.